VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
- Sponsor
- Nanfang Hospital, Southern Medical University
- Study ID
- NCT07052422
- Phase
- PHASE2/PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Conditioning
- Hematopoietic Stem Cell Transplantation (HSCT)
- Myeloid Malignancies
- Older Patients
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Venetoclax (VEN) — DRUGVenetoclax (VEN) was administered at 400mg/day on days -10 to -4.
- Decitabine (DAC) — DRUGDecitabine (DAC) was administered at 20mg/m2/day on days -10 to -8.
- Busulfan (Bu) — DRUGBusulfan (Bu) was administered at 3.2 mg/kg/day on days -5 to -4.
- Fludarabine (Flu) — DRUGFludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.
- Fludarabine (Flu) — DRUGFludarabine (Flu) was administered at 30mg/m2/day on days -6 to -2.
Study Details
The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Key Dates
- Start date
- Jul 15, 2025
- Status verified
- Jul 2025
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: VEN+DAC+Bu2Flu4Venetoclax+Decitabine+Busulfan+Fludarabine
- Active Comparator: Bu2Flu5Busulfan+Fludarabine
Primary Outcome Measure
Disease-free survival (DFS) rate [ Time Frame: 2 year ]
Central Contacts
- Qifa Liu+86-020-62787883
- Qifa Liu+86-020-61641611
Related Studies
- Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised HostsPHASE1 · Recruiting · Children's National Research Institute · Washington D.C., District of Columbia
- A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid MalignanciesPHASE2 · Recruiting · Franziska Wachter · Boston, Massachusetts
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid MalignanciesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas